These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 19903801)
1. Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets. Ip FF; di Pierro I; Brown R; Cunningham I; Handelsman DJ; Liu PY Eur J Endocrinol; 2010 Feb; 162(2):385-90. PubMed ID: 19903801 [TBL] [Abstract][Full Text] [Related]
2. Association of subcutaneous testosterone pellet therapy with developing secondary polycythemia. Rotker KL; Alavian M; Nelson B; Baird GL; Miner MM; Sigman M; Hwang K Asian J Androl; 2018; 20(2):195-199. PubMed ID: 29205178 [TBL] [Abstract][Full Text] [Related]
3. Hematocrit Response and Risk Factors for Significant Hematocrit Elevation with Implantable Testosterone Pellets. Hayden RP; Bennett NE; Tanrikut C J Urol; 2016 Dec; 196(6):1715-1720. PubMed ID: 27287525 [TBL] [Abstract][Full Text] [Related]
4. A Comparison of Secondary Polycythemia in Hypogonadal Men Treated with Clomiphene Citrate versus Testosterone Replacement: A Multi-Institutional Study. Wheeler KM; Smith RP; Kumar RA; Setia S; Costabile RA; Kavoussi PK J Urol; 2017 Apr; 197(4):1127-1131. PubMed ID: 27984109 [TBL] [Abstract][Full Text] [Related]
5. Obstructive Sleep Apnea Is Associated With Polycythemia in Hypogonadal Men on Testosterone Replacement Therapy. Lundy SD; Parekh NV; Shoskes DA J Sex Med; 2020 Jul; 17(7):1297-1303. PubMed ID: 32307242 [TBL] [Abstract][Full Text] [Related]
7. Elevated Dihydrotestosterone is Associated with Testosterone Induced Erythrocytosis. Aghazadeh M; Pastuszak AW; Johnson WG; McIntyre MG; Hsieh TM; Lipshultz LI J Urol; 2015 Jul; 194(1):160-5. PubMed ID: 25596360 [TBL] [Abstract][Full Text] [Related]
8. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice. Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472 [TBL] [Abstract][Full Text] [Related]
9. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. Hajjar RR; Kaiser FE; Morley JE J Clin Endocrinol Metab; 1997 Nov; 82(11):3793-6. PubMed ID: 9360543 [TBL] [Abstract][Full Text] [Related]
10. Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in the First Year of Therapy. Ory J; Nackeeran S; Balaji NC; Hare JM; Ramasamy AR J Urol; 2022 Jun; 207(6):1295-1301. PubMed ID: 35050717 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, Clinical Efficacy, Safety Profile, and Patient-Reported Outcomes in Patients Receiving Subcutaneous Testosterone Pellets 900 mg for Treatment of Symptoms Associated With Androgen Deficiency. McMahon CG; Shusterman N; Cohen B J Sex Med; 2017 Jul; 14(7):883-890. PubMed ID: 28673432 [TBL] [Abstract][Full Text] [Related]
12. Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years. Madsen MC; van Dijk D; Wiepjes CM; Conemans EB; Thijs A; den Heijer M J Clin Endocrinol Metab; 2021 May; 106(6):1710-1717. PubMed ID: 33599731 [TBL] [Abstract][Full Text] [Related]
13. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A; Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets. Pastuszak AW; Mittakanti H; Liu JS; Gomez L; Lipshultz LI; Khera M J Androl; 2012; 33(5):927-37. PubMed ID: 22403285 [TBL] [Abstract][Full Text] [Related]
15. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645 [TBL] [Abstract][Full Text] [Related]
16. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. Zitzmann M; Nieschlag E J Clin Endocrinol Metab; 2007 Oct; 92(10):3844-53. PubMed ID: 17635942 [TBL] [Abstract][Full Text] [Related]
17. Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. Behre HM; Nieschlag E J Clin Endocrinol Metab; 1992 Nov; 75(5):1204-10. PubMed ID: 1430080 [TBL] [Abstract][Full Text] [Related]
18. Testosterone release rate and duration of action of testosterone pellet implants. Kelleher S; Howe C; Conway AJ; Handelsman DJ Clin Endocrinol (Oxf); 2004 Apr; 60(4):420-8. PubMed ID: 15049955 [TBL] [Abstract][Full Text] [Related]
19. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries. Haider A; Zitzmann M; Doros G; Isbarn H; Hammerer P; Yassin A J Urol; 2015 Jan; 193(1):80-6. PubMed ID: 24980615 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. Dobs AS; Meikle AW; Arver S; Sanders SW; Caramelli KE; Mazer NA J Clin Endocrinol Metab; 1999 Oct; 84(10):3469-78. PubMed ID: 10522982 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]